Equities Analysts Offer Predictions for TCRX FY2024 Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Investment analysts at Wedbush raised their FY2024 earnings per share estimates for TScan Therapeutics in a report issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($1.09) per share for the year, up from their prior estimate of ($1.13). Wedbush currently has a “Outperform” rating and a $10.00 price target on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.17) per share. Wedbush also issued estimates for TScan Therapeutics’ Q4 2024 earnings at ($0.25) EPS, Q1 2025 earnings at ($0.25) EPS, Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.01) EPS, FY2026 earnings at ($0.96) EPS and FY2027 earnings at ($0.76) EPS.

Several other research analysts also recently issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of TScan Therapeutics in a report on Tuesday. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of TScan Therapeutics in a research report on Tuesday, August 13th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, TScan Therapeutics has an average rating of “Buy” and an average price target of $12.00.

TScan Therapeutics Stock Down 8.2 %

Shares of TCRX stock opened at $4.82 on Friday. The company has a current ratio of 9.56, a quick ratio of 7.77 and a debt-to-equity ratio of 0.13. The stock has a 50 day simple moving average of $5.33 and a 200 day simple moving average of $6.51. TScan Therapeutics has a 1 year low of $3.73 and a 1 year high of $9.69.

TScan Therapeutics (NASDAQ:TCRX) last posted its earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.02. The company had revenue of $0.54 million for the quarter, compared to the consensus estimate of $1.55 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%.

Insider Transactions at TScan Therapeutics

In related news, Director Barbara Klencke bought 5,000 shares of the company’s stock in a transaction that occurred on Monday, September 23rd. The shares were bought at an average price of $5.29 per share, for a total transaction of $26,450.00. Following the completion of the acquisition, the director now owns 45,000 shares of the company’s stock, valued at $238,050. This trade represents a 12.50 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Zoran Zdraveski sold 164,686 shares of TScan Therapeutics stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $5.78, for a total transaction of $951,885.08. Following the transaction, the insider now owns 4,716 shares in the company, valued at $27,258.48. This represents a 97.22 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders bought 15,000 shares of company stock worth $82,550. Company insiders own 2.76% of the company’s stock.

Institutional Trading of TScan Therapeutics

Large investors have recently made changes to their positions in the business. Tocqueville Asset Management L.P. purchased a new stake in TScan Therapeutics in the 1st quarter valued at about $1,685,000. Bank of Montreal Can acquired a new position in TScan Therapeutics during the 2nd quarter valued at approximately $749,000. Bank of New York Mellon Corp acquired a new position in TScan Therapeutics during the 2nd quarter valued at approximately $682,000. Great Point Partners LLC purchased a new stake in shares of TScan Therapeutics in the 2nd quarter valued at $5,504,000. Finally, Marshall Wace LLP boosted its holdings in shares of TScan Therapeutics by 60.8% in the 2nd quarter. Marshall Wace LLP now owns 307,487 shares of the company’s stock valued at $1,799,000 after acquiring an additional 116,316 shares during the last quarter. 82.83% of the stock is currently owned by institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.